Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 170 200 KRW 2.1% Market Closed
Market Cap: 1.9T KRW
Have any thoughts about
Green Cross Corp?
Write Note

Green Cross Corp
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Green Cross Corp
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Green Cross Corp
KRX:006280
Total Liabilities
â‚©1.5T
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
14%
Celltrion Inc
KRX:068270
Total Liabilities
â‚©2.9T
CAGR 3-Years
19%
CAGR 5-Years
22%
CAGR 10-Years
11%
SK Bioscience Co Ltd
KRX:302440
Total Liabilities
â‚©148.6B
CAGR 3-Years
-21%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Total Liabilities
â‚©125.9B
CAGR 3-Years
-16%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Total Liabilities
â‚©130.8B
CAGR 3-Years
22%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Total Liabilities
â‚©122.1B
CAGR 3-Years
14%
CAGR 5-Years
67%
CAGR 10-Years
N/A
No Stocks Found

Green Cross Corp
Glance View

Market Cap
1.9T KRW
Industry
Biotechnology

Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.

Intrinsic Value
216 615.19 KRW
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Green Cross Corp's Total Liabilities?
Total Liabilities
1.5T KRW

Based on the financial report for Sep 30, 2024, Green Cross Corp's Total Liabilities amounts to 1.5T KRW.

What is Green Cross Corp's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
14%

Over the last year, the Total Liabilities growth was 10%. The average annual Total Liabilities growth rates for Green Cross Corp have been 10% over the past three years , 13% over the past five years , and 14% over the past ten years .

Back to Top